Opus Genetics, Inc. IRD
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Opus Genetics, Inc. (IRD) is a healthcare company listed in the US with a market value of about $385M. In the twelve months to September 30, 2026 it had revenue of $8M and net income of -$137M, a net margin of -1726.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -247%.
About Opus Genetics
Opus Genetics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $3M in 2019 to $14M in 2025, growth of about 29.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 202% over three years (dilution for shareholders). It spends 217% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Revenue growth above 10% last year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $14M | $11M | $19M | $40M | $589000 | $0 | $3M | — | — | — |
| Net income | -$137M | -$50M | -$58M | -$10M | $18M | -$57M | -$25M | -$6M | -$14M | -$25M | -$9M |
| Free cash flow | -$49M | — | — | — | — | — | -$7M | -$4M | — | — | — |
| EPS (diluted) | $-1.48 | $-0.80 | $-2.15 | $-0.46 | $0.87 | $-3.82 | $-5.28 | $-2.17 | $-5.25 | $-11.06 | $-5.17 |
| Net margin | -1726.7% | -349.3% | -523.4% | -52.4% | 44.9% | -9625.3% | — | -205.6% | — | — | — |
| ROIC | — | -234.3% | -923.2% | -16.7% | 38.7% | -99.8% | — | — | — | -81.8% | -76.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 17 analysts is $13.94, 250% above the current price; targets range from $8.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Opus Genetics pay a dividend?
Not currently.
Is Opus Genetics a good stock to buy?
We do not give buy or sell advice. Opus Genetics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.